Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma

The treatment for relapsed/refractory multiple myeloma (RRMM) continues to be challenging despite recent therapeutic advancements. Venetoclax, an inhibitor of the anti‐apoptotic protein BCL‐2, is a promising agent, especially in patients harbouring t(11;14). Our objective was to review our experienc...

Descripción completa

Detalles Bibliográficos
Autores principales: Basali, Diana, Chakraborty, Rajshekhar, Rybicki, Lisa, Rosko, Nathaniel, Reed, Janice, Karam, Maryann, Schlueter, Kristen, Dysert, Hayley, Kalaycio, Matt, Valent, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological Malignancy ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291136/
https://www.ncbi.nlm.nih.gov/pubmed/32012228
http://dx.doi.org/10.1111/bjh.16454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291136/
https://www.ncbi.nlm.nih.gov/pubmed/32012228
http://dx.doi.org/10.1111/bjh.16454

Ejemplares similares